Search PubMed⌕ Search

Biomedical subjects

C Focan

Publications and source records attributed to C Focan.

At least 73 records · Page 4Linked to original sources
PubMed1985

Antipyretic effect and tolerability of suprofen suppositories. Controlled clinical double-blind study with placebo.

The aim of the present study was to investigate the antipyretic effect of alpha-methyl-4-(2-thienylcarbonyl)-phenyl acetic acid (suprofen, Suprol) 300 mg suppositories compared to placebo in patients with fever of various etiology. The trial was designed as a randomized double-blind study including 30 patients per treatment group. After insertion of the suppository, temperatures were measured after 30 min, 1, 2, 3, 31/2, 4, 5, and 6 h. The study was performed at four investigational centers. At the end of the study, a total of 61 patients could be evaluated: 27 on suprofen, 34 on placebo. There were no statistically significant differences in the anamnestic data. The mean age of the subjects on suprofen was 66.5 years, and on placebo 61.3 years. Prior to treatment, the mean temperatures in the two treatment groups were 38.8 and 38.9 degrees C, respectively. In the suprofen group, the temperature dropped to a mean of 37.9 degrees C within 3 h and to 37.6 degrees C within 6 h. The decrease in temperature was less marked in the placebo group; here the mean temperature was 38.4 degrees C after 3 h and 38.2 degrees C after 6 h. Suprofen was found to be superior to placebo throughout the study, the differences being statistically significant after 3 h up to 6 h. The only side effect experienced by a subject on suprofen was vomiting.

Aged↗
PubMed1983

Randomised trial comparing sequential methotrexate (or 5-FU), vinblastine and ifosfamide to vincristine, adriamycin and ifosfamide in advanced lung cancer.

A randomised trial has compared the sequential administration of ifosfamide (with its urinary antidote mesna) combined with methotrexate (or 5-FU in adenocarcinomas) and vinblastine (protocol I) or combined with adriamycin and vincristine (protocol II) in advanced lung cancer. In 29 evaluable cases the results were not influenced by the protocol nor by the histology of the tumors (oat cell v non-oat cell) or the clinical stage (limited v extensive). An overall response rate of 58.6% was obtained (100% in the oat cell and anaplastic carcinomas, 44% in adenocarcinomas, 50% in squamous cell carcinomas) with a clear prolongation of survival in responding groups, whatever the clinical stage.

Aged↗
PubMed1982

Circadian variability of kinetics in a transplantable islet-cell tumor of the golden hamster.

The kinetics of a transplantable islet-cell tumor known to secrete paranormal hormonal compounds without any influence of usual regulatory mechanisms was studied in the golden hamster. It was found that during the 42nd diurnal period of growth, labelling and mitotic indices (peaks at midday), mean grain counts (lower at 4 a.m. and 8 a.m.), and PLM data (shift between G1 and S phase durations) varied significantly. The results are discussed in view of the discrepancy between hormonal release (unaffected by normal triggering factors) and circadian kinetics indicating the persistence of tumoral sensitivity to some control mechanisms. The theoretical importance of the diurnal variability for the correct interpretation of the internal kinetics of tumors is recalled.

Adenoma, Islet Cell↗
PubMed1981

Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors.

The authors treated 51 patients with solid tumours with vindesine 4 mg/m2, generally every third week, in combination chemotherapy protocols scheduled according to diurnal variability of kinetics. No dose-related sensory disorders were observed: On the contrary, motor toxicity appeared cumulative: 1) Early depression of osteotendinous reflexes from the first course onward, with progressive deterioration. No more normal reflexes could be evoked after 55 mg; 2) Early appearance of neurogenic pattern in the electromyograph after 5-10 mg. Progressive alteration with no normal detection recordings after 45 mg; 3) Late slowing down of conduction speeds (normal in 50% of cases up to 55-60 mg). Improvement or even complete recovery of neuropathy was documented following reduction of the unit dose, increased time interval between doses, or discontinuation of the treatment. The drug had to be withheld in only three patients: in two cases a low dosage related to individual sensitivity was being used.

Adult↗
PubMed1979

Sequential chemotherapy and circadian rhythm in human solid tumours. A randomised trial.

Sixty-three patients were randomised into two groups each receiving the same 40-h sequential chemotherapy regimen (methotrexate or 5-FU, followed by vinblastine and cyclophosphamide). In the group receiving infusions of chemotherapeutic agents at times taking into account the circadian rhythm of tumoral proliferation, the antitumoral effectiveness appeared significantly better with respect to both tumoral regressions (85% contrasting with 58% in the other group) and the duration of response and survival.

Adult↗